Evidence map›Paper›PMID 17365270›Full record

ReviewJournal of drug targeting2007

Matrix metalloproteases: underutilized targets for drug delivery.

Deepali G Vartak, Richard A Gemeinhart

Abstract readReview
In one paragraph

Review in Journal of drug targeting, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Review
  2. Veterinary research forum : an international quarterly journal · 2026
    Article
  3. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Matrix remodeling in chronic lung diseases.Matrix biology : journal of the International Society for Matrix Biology · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deepali G VartakDepartment of Biopharmaceutical Sciences, The University of Illinois, Chicago, IL 60612, USA.
Richard A Gemeinhart

Funding

EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015482 · NCRR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BAUMAN, JERRY L · 2000 to 2000
$909k
Targeted Drug Delivery via Microparticle-Drug ConjugatesR03EY014357 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GEMEINHART, RICHARD A · 2003 to 2005
$454k
NCRR NIH HHS C06 RR015482NCRR NIH HHS C06 RR15482NEI NIH HHS EY014357NEI NIH HHS R03 EY014357
6 · The paper itself

Abstract

Pathophysiological molecules in the extracellular environment offer excellent targets that can be exploited for designing drug targeting systems. Matrix metalloproteases (MMPs) are a family of extracellular proteolytic enzymes that are characterized by their overexpression or overactivity in several pathologies. Over the last two decades, the MMP literature reveals heightened interest in the research involving MMP biology, pathology and targeting. This review describes various strategies that have been designed to utilize MMPs for targeting therapeutic entities. Key factors that need to be considered in the successful design of such systems have been identified based on the analyses of these strategies. Development of targeted drug delivery using MMPs has been steadily pursued; however, drug delivery efforts using these targets need to be intensified and focused to realize the clinical application of the fast developing fundamental MMP research.

Indexed as

Drug Delivery SystemsAnimalsBiotransformationHumansMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesProdrugsMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesProdrugs

Identifiers

PMID17365270
PMCPMC3782085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.